INTRODUCTION
Celiac disease (CD) is a condition of sensitivity to gluten (a mixture of proteins in wheat, rye and barley) causing an immunologically based enteropathy in genetically predisposed subjects. This disease manifests both cellular and humoral immunity responses; humoral antibodies are used in diagnosis and follow-up (17, 26, 50, 51) . CD may also be associated with other inherited diseases involving autoimmunity mechanisms, such as type I diabetes mellitus, Down's syndrome and thyroid conditions, especially Basedow-Graves' disease and Hashimoto's thyroiditis (18, 26, 27, 50, 53, 56) . An association between CD and autoimmune rheumatologic diseases has been posited by various authors, but this possibility remains controversial, since these reports are usually based on descriptive case reports (19, 22, 26, 40, 41) . Although previously considered rare, CD is being diagnosed with increasing frequency worldwide; prevalence rates are 0.33% to 1.5% in Europe (6, 49) and 0.7% to 1.3% in the United States (8, 48, 50) . Studies in various regions of Brazil have pointed to prevalence rates ranging from 1/273 to 1/1000, depending on the study population (13, 37, 42, 46) . The growing number of diagnosed CD cases is due not only to an increased recognition of atypical forms, but also to more readily available serological and endoscopic diagnostic methods at present. In Brazil, however, laboratory techniques for serological tests are generally not standardized; their accuracy thus remains low for screening purposes when selecting patients for intestinal biopsies (1, 26) . The purpose of this study was to help improve the assessment of serum tests for CD, especially antigliadin and antiendomysium antibodies, in adult and pediatric patients with autoimmune rheumatologic diseases.
METHODS
A clinical cross-sectional study of 190 adult and pediatric patients was carried out in the Rheumatology Outpatient Unit of the Clinical Hospital (Hospital das Clínicas), Federal University of Minas Gerais, in Belo Horizonte, MG, Brazil, from November 2005 to February 2008. Individuals with a confirmed diagnosis of systemic lupus erythematous (SLE), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA) and spondyloarthropathies were included in this study.
Participants signed a free informed consent form. The Research Ethics Committee of the Federal University of Minas Gerais approved this study.
Each participant answered a questionnaire; blood was taken for laboratory tests when the patients were scheduled for hematologic tests to control their rheumatologic condition.
Laboratory analysis comprised the ELISA immunoenzyme assay testing for IgA and IgG antigliadin antibodies (AGAA, AGAG) as described in a modified Volta et al. (54) method (1) . The cutoff point for AGAA test positivity was an optic density of 0.041 and over; the corresponding cutoff point for AGAG test positivity was 0.140 (1) . Antiendomysium antibodies were tested using the indirect immunofluorescence technique as described by one of the modified Chorzelski et al. (4) methods. (1) . Sera were tested at a 1:2.5 dilution; sera that showed positive fluorescence at 250x magnification were diluted to 1:5 and 1:40, and the test was repeated. EmA-positive patients were those with sera that fluoresced in an endomysial "honeycomb" pattern at a 1:40 dilution (1) . IgA (tTG) tissue antitransglutaminase antibodies were tested in EmA-positive sera at 1:40 using the INOVA QUANTA Lite h-tTG IgA kit (INOVA Diagnostics Inc, San Diego, California, USA).
Nephelometry (IMMAGE Immunochemistry Systems IGA, Beckman Coulter Inc, Fullerton, California, USA) was used for dosing IgA class serum immunoglobulins in patients that were AGGA and EmA-negative and AGAG-positive (32) . IgA reference values for adults were 82 to 453 mg/dL.
EmA-positive patients (1:40 dilution) and AGAA or AGAG-positive patients underwent upper digestive endoscopy with duodenal biopsies, examined by an expert pathologist. At least six mucosal fragments were taken from the second portion of the duodenum below the papilla using a common 6 mm biopsy forceps (Fujinon); a Fujinon EG 200FP gastroscope was used for examination. Histological criteria for systematic sample analysis were those of the North American Gastroenterology Association (50) which match the Marsh criteria (35) . Files of AGAA, AGAG or EmA-positive patients were studied in search of data on anemia; patients were inquired directly as to the presence of chronic diarrhea to find clinical symptoms suggesting the presence of CD. Correlations were sought among positive serum tests and the use of prednisone and immunosuppressant drugs.
The Kruskal-Wallis test was applied for statistical comparisons among more than two groups. The Mann-Whitney test was applied for comparisons between two groups. The chi-square and Fisher's exact test were applied to compare qualitative variables. Spearman's correlation coefficient (rho) was applied to assess the intensity of relations (rho≤0.3: weak correlation; 0.3<rho≤0.6: moderate correlation; 0.6<rho<0.8: moderate to strong correlation; rho≥0.8: very strong correlation). The chi-square test was applied to investigate associations among categorical variables. The significance level for all statistical tests was 5%.
RESULTS
There were 190 patients, 141 of which (74.2%) were female and 49 (25.8%) were male. The mean age was 38.8 years; the standard deviation was 17.7 years, the median age was 39.5 years, the maximum age was 76 years and the minimum age was 2 years. Among these patients 69 (36.3%) had SLE, 48 (25.3%) had RA, 32 (16.8%) had JRA, and 41 (21.6%) had spondyloarthropathies.
Patients were allocated to four groups: group 1 -SLE patients n = 69 (36.3%); group 2 -RA patients n = 48 (25.3%); group 3 -JRA patients n = 32 (16.8%); group 4 -spondyloarthropathy patients n = 41 (21.6%) Specific diagnoses were as follows: ankylosing spondilitis (27 cases), Reiter's reactive arthritis (1 case), psoriatic arthritis (6 cases), Crohn's disease enteropathy (1 case), and undifferentiated spondyloarthropathies (6 cases).
There were statistically significant differences in age among the four groups; JRA usually affects younger subjects before age 16 years, which is a necessary criterion for this diagnosis. There was also a statistically significant gender difference among the four groups, as males predominated only in the spondyloarthropathy group.
IgA and IgG antigliadin antibodies
There were no statistically significant differences among groups in relation to AGAA and AGAG (Table 1) .
Four patients tested AGAA-positive: the serum optic density was 0.042 in an RA patient, 0.051 in a JRA patient, 0.076 in an SLE patient, and 0.102 in another RA patient. All were AGAG and EmA-negative, and did not present diarrhea or anemia.
Three patients tested AGAG-positive: the serum optic density was 0.148 in an RA patient, 0.163 in an SLE patient, and 0.197 in a patient with Crohn's disease associated spondyloarthropathy. Serum IgA levels in these adults patients were 177 mg/dL, 510 mg/dL and 398 mg/dL; thus, this immunoglobulin was not decreased in any of them. All three tested negative for AGAA and EmA, and did not present diarrhea or anemia.
IgA antiendomysium antibodies
EmA was positive in 49.5% and negative in 50.5% of the samples at a 1:2.5 dilution.
Testing was done at a 1:5 dilution only on sera that had tested positive at 1:2.5; in this case, 21.7% of the samples were positive.
At 1:40, 11 sera tested positive (5.8%); three were SLE patients, four were RA patients and four patients had ankylosing spondilitis. None of these 11 patients presented diarrhea or anemia ( Table 2 ).
IgA and IgG antigliadin antibodies and IgA antiendomysium antibodies
There was a significant difference between EmA positive results at 1:2.5 and 1:40 dilution relative to the AGAA; this difference, however, was not present relative to the AGAG (Table 3) . Thus, higher AGAA optic density readings increase the possibility of higher EmA positive results as shown by Spearman's correlation above.
Tissue IgA antitransglutaminase antibodies
All 11 EmA positive sera at a 1:40 dilution were also tested for tTG, and all were negative for these antibodies. The tTG was not tested in other patients.
IgA and IgG antigliadin antibodies and medication
The 190-patients sample was divided into two medication groups: patients in the first group took only non-steroidal anti-inflammatory drugs and/or chloroquine diphosphate (n = 45); patients in the second group took prednisone and/or immunosuppressants (n = 145) ( Table 4) .
Patients were further divided into two groups to assess the dose effect of prednisone on antibodies: one group consisted of patients taking non-steroidal anti-inflammatory drugs and/or analgesics and/or chloroquine diphosphate and/or prednisone ≤5 mg/day (n = 65); the other group consisted of patients taking prednisone >5 mg/day and/or immunosuppressants (n = 125) ( Table 5) .
There was no association between AGAA and AGAG optic density readings and these groups taking different drugs.
Antiendomysium antibodies and medication
EmA positivity at a 1:2.5 dilution was compared with medication use in the same groups of patients; no association was found at this dilution (Table 6 ). However, there was a significant association between EmA positivity and medication use at 1:40 dilution. The proportion of EmA-positive subjects taking only non-steroidal anti-inflammatory drugs and/or chloroquine diphosphate was higher compared to patients taking other drugs. Thus, use of immunosuppressants and/or prednisone correlated with negative EmA results. This association became more evident when patients were subdivided according to the daily dose of prednisone (Table 7) . Paimela et al. (44) studied 78 RA patients and found that AGA (IgA and/or IgG) was positive in 37% of these subjects and in 12% of controls. Histological studies of the intestine did not reveal enteropathies in any subject.
Feighery et al. (11) undertook EmA testing in 53 RA patients and 46 SLE patients. No SLE patient tested positive; there was a single positive case in the RA group, but no intestinal biopsy was done. On the other hand, guinea-pig enzyme tTG testing yielded an 11% positive rate in RA subjects and a 22% positive rate in SLE subjects; CD was not confirmed in any of these patients.
Rensch et al. (47) found a 23% positivity rate for at least one class of antigliadin antibodies in 103 SLE patients; none of these patients had intestinal signs of CD. EmA testing was negative in all cases.
Marai et al. (34) tested 100 SLE patients for tTG using human recombinant enzymes and found a single case of CD.
Kallikorm et al. (24) studied 74 hospitalized patients with various spondyloarthropathies and found one case of CD. AGAA were positive in 12% of these cases, AGAG were positive in 4%, and EmA tested positive only in the single confirmed enteropathy case.
Lindqvist et al. (31) found 5 CD cases in 144 psoriatic arthritis patient (4.4% prevalence rate) in this sample. None of these patients were EmA-positive, which was attributed to mild intestinal vilosity atrophy in their histological analysis. All cases were AGAA-positive; antibody titers in these patients with arthritis were significantly higher compared to controls after excluding patients with CD.
JRA is one of the most common rheumatic diseases in children, although there is no consensus on whether the prevalence of CD is higher or not in such patients (38) . George et al. (14) estimated a 0.4% to 2% prevalence of CD in JRA patients. Stagi et al. (52) found 10 CD cases (6.6%) in 151 JRA pediatric patients, a much higher percentage than that of the local population. Similarly, Lepore et al. (30) found 4 EmA-positive cases in 119 JRA children; 3 of these children had asymptomatic intestinal vilosity atrophy, a 2.5% prevalence rate of CD in this sample.
Serum dilutions in antiendomysium antibody testing for defining positive results vary widely among authors. Kotze et al. (25) used a 1:2.5 dilution; Johnston et al. (23) used a 1:5 dilution; Leon et al. (29) used a 1:10 dilution; and Ghedira et al. (15) used a 1:50 dilution. Bahia et al. (1) found 39 positive EmA tests at a 1:2.5 dilution in 173 controls with no gastrointestinal complaints; none of them had CD. At a 1:40 dilution none of these patients tested positive for EmA. Based on their statistical analysis, these authors concluded that 1:40 would be the ideal dilution to identify CD patients.
We found that the serum dilution clearly influenced the positive EmA results (fluorescence pattern indicating a positive result), as follows: at a 1:2.5 dilution the positive rate was 49.5%; at a 1:5 dilution, the positive rate was 21.7%; and at a 1:40 dilution, the positive rate was only 5,8%.
There may be more than one explanation for the absence of histological findings suggesting CD and the tTG-negative results in the 11 EmA-positive patients in our sample: one could be the presence in these patients of other IgA class autoantibodies not directed against tissue transglutaminases, which would bind to 
Antiendomysium and antigliadin antibody positivity and histological studies of the duodenum
Upper digestive endoscopies with duodenal biopsies were carried out in 9 of 11 patients with positive antiendomysium antibodies and in all 7 patients with positive antigliadin antibodies (IgA or IgG). Testing was not done in 1 patient that died; another patient refused endoscopy.
Endoscopy of the bulbus and second portion of the duodenum were within normal limits macroscopically. No significant histological changes were found in the samples of duodenum (all were classified as March 0); thus, all patients were considered as having no histological signs of CD.
Assuming that no patient presented CD, the specificity of AGAA and AGAG were calculated at 97.9% and 98.4%. Similarly, the specificity of EmA testing in our sample was 94.2%.
DISCUSSION
Reports in the literature on the prevalence of CD in adult and child rheumatologic diseases are generally not uniform (3, 5, 7, 9, 22) . Most papers that mention any association between these conditions are based on small samples or case reports.
Fasano and Catassi (9) estimated that the prevalence of CD among RA patients ranged from 1.5% to 7.5%. Francis et al. (12) studied 160 British patients with RA and found a single case of CD among them; a 0.63% prevalence, equal to that of the country as a whole. Similarly, Nisihara et al. (43) in Brazil studied 85 RA patients and 97 healthy controls, and found no EmA positive results in any of them.
human umbilical cord antigens and fluoresce in a similar pattern to that of CD. It should be noted that this group consisted of patients with rheumatologic autoimmune diseases in which a variety of autoantibodies -such as anti-smooth muscle antibodies -were produced, which generally make it harder to test EmA at lower dilutions (28, 33, 55) . Anti-smooth muscle antibodies and other autoantibodies were not tested in this study. Negative tTG results in EmA-positive patients suggest that this second test is more specific in rheumatologic patients with autoimmune disease. All subjects would have had to be tested to demonstrate this possibility.
A less likely explanation for positive EmA tests in our sample could be a less than adequate interpretation of slides, given the subjective nature of the evaluation of fluorescence, or even procedural failure when carrying out the tests. The same examiner that interpreted the slides found no positive results in a previous study of 312 patients without CD, using the same material and methods at a 1:40 dilution in the same laboratory (1) . Positive EmA tests in subjects with no histological findings for CD may indicate a latent form of this condition that may manifest in future. Serological and histological follow-up of these patients across the years could confirm this possibility.
EmA positivity was related with AGAA-testing optic density readings, but not with IgG testing. In other words, EmA-positive sera had higher AGAA readings compared to negative sera for these antibodies. This appears to reflect an increased production of a variety of IgA class antibodies in EmA-positive subjects.
Although controversial, many authors have suggested that prednisone and other immunosuppressants, especially at high doses, may decrease antibody production (2, 10, 20, 45) . However, there was no significant difference in AGAA and AGAG test optic density readings in our patients using these drugs or not.
On the other hand, prednisone and other immunosuppressant drug use were inversely related with EmA positivity: patients taking these drugs had a lower rate of positive EmA tests, which suggested that fewer of the antibodies detected by fluorescence in this group were being produced.
Histology of duodenal biopsies in our sample did not show significant changes. This was probably due to the absence of CD or other enteropathies. We cannot, however, discard completely the influence of prednisone and other immunosuppressants on our results, since these drugs may decrease structural and inflammatory alterations of the small intestine (16, 36, 39, 50) .
CONCLUSION
In conclusion, our study suggests that positive AGAA, AGAG or EmA results generally do not imply in the presence of CD in patients with autoimmune rheumatologic disease with no classical clinical manifestations of this enteropathy. Further studies are needed to assess the prevalence of CD in rheumatologic patients with greater accuracy.
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